Gilead says its twice-yearly shot cut HIV infections by 96% in trial
A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug.Nardus Engelbrecht | APGilead’s twice-yearly shot reduced HIV infections by 96% in a second large study, the company…